Recent studies have described chromosome 2p gain as a recurrent lesion in chronic lymphocytic leukemia (CLL). We investigated the 2p gain and its relationship with common prognostic biomarkers in a prospective series of 69 clinical monoclonal B-cell lymphocytosis (cMBL) and 218 early stage (Binet A) CLL patients. The 2p gain was detected by FISH in 17 patients (6%, 16 CLL, and 1 cMBL) and further characterized by single nucleotide polymorphism-array. Overall, unfavorable cytogenetic deletions, i.e., del(11)(q23) and del(17)(p13) (P 5 0.002), were significantly more frequent in 2p gain cases, as well as unmutated status of IGHV (P < 1 3 10 24 ) and CD38 (P < 1 3 10 24 ) and ZAP-70 positive expression (P 5 0.003). Furthermore, 2p gain patients had significantly higher utilization of stereotyped B-cell receptors compared with 2p negative patients (P 5 0.009), and the incidence of stereotyped subset #1 in 2p gain patients was significantly higher than that found in the remaining CLLs (P 5 0.031). Transcriptional profiling analysis identified several genes significantly upregulated in 2p gain CLLs, most of which mapped to 2p. Among these, NCOA1 and ROCK2 are known for their involvement in tumor progression in several human cancers, whereas among those located in different chromosomes, CAV1 at 7q31.1 has been recently identified to play a critical role in CLL progression. Thus, 2p gain can be present since the early stages of the disease, particularly in those cases characterized by other poor prognosis markers. The finding of genes upregulated in the cells with 2p gain provides new insights to define the pathogenic role of this lesion. Am. J. Hematol. 88:24-31, 2013. V V C 2012 Wiley Periodicals, Inc.
Introduction
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease having an indolent course in most patients who may survive for many years without treatment, or showing an aggressive and rapidly progressive outcome in others [1, 2] . Although the current Rai [3] and Binet [4] staging systems identify patients with high-risk disease, they do not prospectively distinguish patients with potentially evolving disease from those destined to remain stable for decades.
A number of cellular and molecular markers help to classify CLL into biologically and clinically distinct subgroups, and to predict the clinical course of the disease at diagnosis [5] . CLL patients with unmutated (UM) immunoglobulin heavy chain variable (IGHV) region genes (>98% homology to germline sequences), increased expression of the CD38 cell surface antigen, or increased expression of the 70-kd zeta-chain T-cell receptor-associated protein kinase (ZAP-70) experience a shorter therapy-free interval, and a more aggressive behavior [6] [7] [8] . Specific recurrent chromo-Additional Supporting Information may be found in the online version of this article. 1 somal abnormalities, traditionally detected by fluorescence in situ hybridization (FISH), such as deletions at 13q14, 11q23, 17p13, 6q21-23, and trisomy 12, may also represent important independent biomarkers for disease progression and survival [9] [10] [11] [12] [13] . Whole genome analyses have provided additional information on novel recurrent alterations in CLL, such as gain of the short arm of chromosome 2 (2p). In particular, these studies focused on putative oncogenes such as BCL11A, REL, and MYCN, located at 2p, as possible deregulated targets [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . However, with the exception of a very recent report [25] , most of the available and representative studies investigating 2p gain have been performed in quite heterogeneous and retrospective series of patients encompassing various stages of the disease, making it difficult to ascertain the involvement and role of 2p gain in the disease.
In this study, we attempted a comprehensive molecular characterization of 2p gain in a large and representative prospective series of clinical monoclonal B-cell lymphocytosis (cMBL) and Binet stage A CLL patients. Detection of the 2p gain was determined by FISH using locus specific probes and was correlated with the major biological, molecular, and genomic prognostic markers of the disease. Furthermore, microarray analyses were carried out to characterize the genomic profile of positive cases and transcriptional profiles associated with 2p gain. Methods
Patients. The 287 consecutive CLL patients included in this study were enrolled in the Gruppo Italiano Studio Linfomi (GISL) O-CLL1 multicentre trial, that currently includes 463 cases (registered at Clini-calTrials.gov, accession # NCT00917540). Written informed consent was obtained from all patients in accordance with the declaration of Helsinki and the study was approved by the local Ethics Review Committee (Comitato Etico Provinciale, Modena, Italy). The inclusion criteria was a diagnosis of typical CLL in accordance with the 1996 National Cancer Institute-sponsored Working Group (NCI-WC) guideline criteria for CLL [26] , based on morphological and phenotypical analyses (i.e., the co-expression of CD19, CD5, and CD23 and weak SmIg, and the monotypical expression of k or k light chains by neoplastic cells). At the time of enrollment, all patients had an absolute lymphocyte count (ALC) of at least 5,000 3 10 9 /L (range 5,000-100,000 3 10 9 /L); 213 (77%) patients were at Rai 0 stage; 42 (15.1%) at stages I and 21 (7.6%) at stage II. On the basis of the new NCI-WC criteria [27] , among 213 Rai 0 patients subjected to immunophenotypic CD51/ CD191 analysis, 69 cases (32%) showed a clonal B-cell count < 5,000 3 10 9 /L and were reclassified as CLL-like clinical MBL (cMBL) [28] . Among cMBLs, 31 patients were males and 36 were females; the mean and median age at diagnosis was 60 and 62 years, respectively (range, . In CLL cases, the mean and median age was 59 and 60 years (range, 30-70 years), and 138 patients were males and 80 were females.
No conventional cytogenetic (G-banding) findings were available. The median follow-up of this series was 30 months.
Sample preparation, molecular, and FISH analyses. Peripheral blood mononuclear cells from CLL patients were collected within one year from diagnosis and were isolated by Ficoll-Hypaque (Seromed, Biochrom KG, Berlin, Germany) density-gradient centrifugation. For FISH analysis and gene expression profiling experiments, CLL cells were enriched by negative selection with the EasySep-Human B cell enrichment kit without CD43 depletion (Stem Cell Technologies, Voden Medical Instruments SPA, Milano, Italy) using the fully automated protocol of immunomagnetic cell separation with RoboSepTM (Stem Cell Technologies).
The proportion of CD5/CD19/CD23 triple positive B cells in the suspension was determined by direct immunofluorescence with antibodies for CD19-FITC (BD Biosciences Pharmigen, San Josè, CA), CD23-PE (BD Biosciences), and CD5-PC5 (Beckman Coulter Immunotech, Marseille, France). Sample purity of B-cells was greater than 90% for all experiments.
CLL IGHV gene usage and mutation were determined as previously described and the 98% homology cut-off value was used to discriminate the mutated (M) or unmutated (UM) IGHV configuration [29] ; the identification of distinct subsets with stereotyped BCRs was performed as previously reported [30] . ZAP-70 and CD38 expression was examined by flow-cytometry as previously described [31, 32] and cut-off points were of 30 and 20%, respectively. The FISH study was performed using the protocol provided by the manufacturer of the multicolor probes LSI D13S25/LSI 13q34, LSIp53/CEP17, LSI ATM/CEP11, and CEP12 (Vysis Inc., Downers Grove, IL) as previously described [33] , for the detection of 13q14, 17p13, and 11q22-q23 deletions and trisomy 12, respectively. On the basis of single nucleotide polymorphism (SNP) arrays data previously reported by us [34] , specific BAC clones RP11-606L8 (BCL11A; 2p16.1) and RP11-368O18 (2p24.1), selected from the University of California Santa Cruz (UCSC) Genome Browser Database (http://genome.ucsc.edu/), were used for the identification of 2p gain. FISH analyses were performed according to previously described protocols [35] . All contingency analyses were performed by Fisher's Exact test and differences between groups were analyzed using the Mann-Whitney test. A P value < 0.05 was considered significant for all statistical calculations.
SNP-array mapping analysis. Two hundred and fifty nanograms of total genomic DNA were processed and hybridizations were performed using Affymetrix GeneChip 1 Human Mapping 250K NspI microarrays according to manufacturer's instructions (Affymetrix, Santa Clara, CA). Images were acquired using Affymetrix GeneChip 1 Operating System version 1.4. The entire procedure for the copy number (CN) estimation has been fully described previously [36] . Briefly, the raw data for individual SNPs were extracted from CEL files and converted into signal intensities using GTYPE 4.1 and Affymetrix Copy Number Analysis Tool (CNAT 4.0.1) softwares using the Hidden Markov Model algorithm with a genomic smoothing window set to 0. After the pre-processing, piecewise constant estimates of the underlying local DNA CN variation was calculated using the DNAcopy Bioconductor package, which looks for optimal breakpoints using circular binary segmentation (CBS) [37] , and the median of the estimated profiles was scaled back to a nominal multiplicity of two. After scaling, a k-means clustering algorithm was used on the cumulative profile of all the data to determine the thresholds for inferring discrete CN values were as follow: CN higher than 2.1 and 2.6 corresponded to gain and amplification whereas CN below 1.9 and 1.29 to loss and biallelic deletion, respectively.
Gene expression profiling and data analysis. Total RNA extraction, preparation of DNA single-stranded sense target, hybridization to Gen-eChip 1 Gene 1.0 ST Array (Affymetrix) and scanning of the arrays (7G Scanner, Affymetrix) were carried out according to manufacturer's protocols. Log2-transformed expression values were extracted from CEL files and normalized using NetAffx Transcript Cluster Annotations, Release 32 (June 2011) and robust multi-array average (RMA) procedure in Expression Console software (Affymetrix). The expression values of transcript cluster ID specific for loci representing naturally occurring read-through transcriptions or mapped to more than one chromosomal location were summarized as median value for each sample. Supervised analyses were performed as previously described (0% of accepted median false discovery rate with 1,000 permutations) using the Significant Analysis of Microarrays software (SAM version 4.00; Excel front-end publicly available at http://www-stat.stanford.edu/tibs/ SAM/index.html) [38] . The functional annotation analysis on the selected lists was performed by the Database for Annotation, Visualization, and Integrated Discovery (DAVID) version 6.7 (U.S. National Institutes of Health at (http://david.abcc.ncifcrf.gov/) tool.
The genotyping and gene expression data are available at NCBI's Gene Expression Omnibus (GEO; http://www.ncbi.nlm.mih.gov/geo) through GEO Series Accession no. GSE 38618.
Real-time quantitative polymerase chain reaction. ROCK2 and CAV1 expressions were analyzed in purified CD191 cells by means of real-time quantitative RT-PCR (Q-RT-PCR). Total RNA was converted to cDNA using M-MLV reverse transcriptase (Invitrogen). Inventoried TaqMan Gene Expression Assays (Hs00178154_m1 for ROCK2 and Hs00971716_m1 for CAV1) and the TaqMan Fast Universal Master Mix were used according to manufacturer's instructions (Applied Biosystems, Foster City, CA). UBC TaqMan Gene Expression Control (Hs00824723_m1) (Applied Biosystems) was used as the internal control. The measurement of gene expression was performed using the Applied Biosystems StepONE Real-Time PCR System. All the samples were run in duplicate. Data were expressed as 2 2DCt (Applied User Bulletin No. 2).
Results

Identification of 2p gain in cMBL and CLL patients
We investigated the occurrence of 2p gain in a series of 287 newly diagnosed, untreated CLL cases included in the Italian multicentre prospective clinical trial O-CLL1. The major patients' features are reported in Table I, whereas  the biological and molecular characteristics of patients harboring the 2p gain are summarized in Tables I and II . Gain of 2p was detected by FISH in 17 patients (6%) with a median percentage of positive nuclei of 60% (range, 7-100%).
The number of additional copies was one in all the positive cases. Both FISH probes detected chromosomal gains in all but two cases (CA0058 and PG0065) in which only the centromeric probe (RP11-606L8) was gained. We observed the 2p gain as a single aberration in six cases. In the remaining cases, 2p gain was associated with trisomy 12 or 13q monoallelic deletion in two and three patients, respectively; with 17p13 and 13q monoallelic deletions in two cases; with 11q23 and 13q monoallelic deletions in three cases; with a 11q23 and 13q biallelic deletions in one case. Overall, there was a higher prevalence of unfavorable cytogenetic deletions, i.e., del(11)(q23) and del(17)(p13) (P 5 0.002, Table I ) in 2p positive patients. Interestingly, only three of the 2p positive patients were female, confirming previous findings of a male gender predominance in poor prognosis patients [7] .
Notably, UM IGHV status and ZAP-70 and CD38 positive expression were significantly more frequent in 2p positive cases compared to 2p negative patients (17/17, 100%; 16/ 17, 94% and 14/17, 82%, respectively) ( Table I ). The frequency of 2p gain in cMBLs (1/69; 1.4%) was lower than that of CLL patients of our series (16/207, 7 .7%) as well as of the Rai 0 cases (12/144, 8.3%), albeit not significant. A significantly more frequent utilization of stereotyped BCR was observed in CLL with 2p gain compared with the normal ones (10/16, 62% vs. 76/263, 29%) (P 5 0.009, Table I ). Interestingly, the utilization of stereotyped subset #1 was significantly more frequent in 2p positive patients (3/10, 30%) than that of all the other stereotyped CLLs (4/ 76, 5%) (P 5 0.031, Table I ), whereas no statistically significant association was demonstrated with IGHV gene usage (data not shown).
Finally, we did not find any significant difference in the time to first treatment between the 2p positive and 2p negative CLLs (P 5 0.320). This finding was also confirmed after exclusion of cMBL cases from the analysis (P 5 0.480) (Supporting Information Fig. 1 ).
SNP-array analysis of CLLs with 2p gain
The genomic profile was investigated in 10 CLL patients with 2p gain. The lesion was confirmed in all but one case (LL0130), which case showed a very low proportion of cells carrying the alteration (7%), in all likelihood not detectable by microarray technology. Figure 1A shows the extension of the 2p gain in the 9 patients. Specifically, the gain involved the whole short arm of chromosome 2 in six patients (TF0001, NM0156, MB0065, VM0107, CP0104, DA0094); most part of the short arm in two cases (GP0171 and PG0028); and a smaller region (31.7 Mb) encompassing cytobands 2p16.1-p11.1 in a single patient (CA0058). The minimal gained region was 10.2 Mb in length from 2p16.1 to p14 and included the two putative oncogenes BCL11A and REL. The MYCN gene was involved in all but one case (CA0058) (Fig. 1A) . SNP-array results were fully concordant with FISH analyses in detecting the major genetic lesions except in case PG0028 which carried a 13q monoallelic deletion. This was present in only 24% of cells and could be observed solely by FISH ( Fig. 1B and Supporting Information Table I for more  details) .
Transcriptional signature associated with the 2p gain Gene expression profiling was performed in the 30 cMBL and 106 Binet stage A CLL patients including 12 cases with 2p gain. The major genetic lesions and IGHV muta- Figure 2A . Supervised analysis revealed 96 differentially expressed genes between 2p positive and 2p negative patients; the majority of these genes (94%) were up-regulated in 2p positive patients, and 21 of them mapped at the short arm of chromosome 2 (Supporting Information Fig.  2A ). When a multiclass supervised analysis was performed comparing UM, M and 2p positive patients, we observed a strong similarity between the transcription pattern of UM and 2p positive patients (Supporting Information Fig. 2B ). Consequently, to avoid bias factors introduced by the fact that all the 2p positive patients analyzed by gene expression were UM and did not harbor trisomy 12, a supervised analysis comparing twelve 2p positive and thirty-three 2p normal UM CLLs without trisomy 12 was carried out ( Fig.  2A ). There were differences in the expression of 18 genes, all of which were upregulated in 2p gained patients and all but two (CAV1 and PSD3) mapping at 2p (see Table III ).
The ROCK2 and CAV1 genes were selected for Q-RT-PCR validation. The Q-RT-PCR analyses were performed on a panel including 10 2p positive and 30 2p negative samples from our dataset. The correspondence between the microarray and Q-RT-PCR data were evaluated by assessing the linear correlation coefficients of the expression levels determined by the two analyses: the coefficients were 0.84 for the ROCK2 probe and 0.92 for the CAV1 probe, thus indicating almost complete concordance for both genes (Fig. 2B) .
Discussion
Previous retrospective studies based on FISH, comparative genomic hybridization (aCGH) and SNP array identified 2p gain as a recurrent alteration in CLL associated with advanced Binet stage, UM status of IGHV gene and 17p13 deletion [12, [14] [15] [16] [17] [18] [19] [20] [21] [22] 24, [39] [40] [41] [42] .
In this study carried out on a cohort of cMBL and early stage CLL, 2p gain was detected in a fair proportion of cases (6%), indicating that this lesion may appear since the early stages. Interestingly, 2p gain was detected as the sole cytogenetic lesion in six cases: this is unlike most reports [14, 15, 19, 20, 39] where 2p gain was always detected together with the most frequent cytogenetic lesions. In the remaining 11 cases, 2p gain was significantly associated with the presence of 11q deletion (P 5 0.016). Similar result was also reported by Rinaldi et al. [23] .
The choice of investigating early cases has conceivably facilitated the detection of cases with 2p gain only, since a number of cytogenetic changes appear later during the disease course and it is thus not surprising that different cytogenetic changes coexist in advanced stages as well as in cases characterized by unfavorable prognostic markers [40] . The finding of 2p gain in early stages of disease in the absence of other major lesions may indicate a possible role for 2p gain in disease progression. Furthermore, it should be noted that in some patients the 2p gain was detected in a relatively small fraction of nuclei compared to the percentage of leukemic cells carrying additional rearrangements. Taken together, these findings further support the suggestion that 2p gain may represent both an early lesion in some CLL patients or a secondary alteration associated with concurrent abnormalities in others. The association with unfavorable prognostic factors did not reflect on the risk of progression in our cohort, where no significant difference between 2p gain and 2p normal CLLs were evidenced in the time to first treatment. How- ever, we cannot exclude that different prognostic information could be obtained with longest follow-up. Of note is also the finding that the proportion of cases with 2p gain was higher than that (2-3%) recently reported by Deambrogi et al. [15] in their retrospective series of newly diagnosed CLLs investigated by FISH. Most likely, this discrepancy could be due to the fact that our analyses were performed on highly purified B cells that definitely improved the ability of FISH to detect the alteration even in small subclones (see Table II ). In addition, there was an association with certain stereotyped BCRs and in particular with subset #1, which characterizes cases with more unfavorable course [30] . The reasons for this association are not easily apparent. However, based upon observations that unmutated CLL cells are more easily stimulated by signals delivered by the BCR, express surface activation markers and have a more active in vivo turn-over [43] , it can be speculated that the more intense proliferation of the cells from this CLL subgroup facilitates the accumulation of 2p gain as well as of other cytogenetic abnormalities. Overall, our findings confirm the evidence that 2p gain is associated even at early stage disease with a subgroup of CLLs characterized by negative biomolecular prognostic markers; this evidence is further supported by the almost absence of 2p gain in cMBL. The low frequency of 2p gain in cMBL also could be explained based upon differences in clonal expansion capacities. Indeed, cMBL with unmutated BCR are more likely to progress rapidly into full blown CLL.
Although previous studies suggested various genes (REL, BCL11A, MYCN, ALK, and more recently ACP1) [14] [15] [16] [17] [18] [19] [20] [21] [22] 24] as potential targets of the 2p gain, no firm data supporting this notion are available. We used a microarray technology approach in order to characterize the putative critical region of 2p gain as well as the deregulated genes in the context of the chromosomal alteration. The minimally duplicated region in our cohort as assessed by SNP-array showed that three of the putative target genes, BCL11A, REL, and MYCN, were involved in all but one case, which was specifically devoid of the MYCN gain. However, no differences in BCL11A, REL, and MYCN expression levels between 2p gain positive and 2p negative patients was observed, nor differences of ALK gene expression were noticed. Particularly, we were not able to detect a significant up-regulation of the MYCN gene as described by others based on Q-RT-PCR or microarray [14, 24] : the limited number of 2p positive CLLs, the higher prevalence of clinical advanced stages in those previous studies as well as a different generation array could explain this discrepancy. Finally, the ACP1 gene recently described by Dequin et al. [20] as commonly gained (25%) in CLL, was gained in all but one case analyzed by SNP-array.
This data demonstrate that a remarkable gene dosage effect can be associated with the 2p gain and that novel genes can be up-regulated as a possible consequence of the 2p gain. Among these we should mention NCOA1 (nuclear receptor coactivator (1), a transcriptional coactivator belonging to the SRC family which is deregulated in breast and prostatic cancer and may potentiate gene expression by acting as a coactivator for nuclear hormone receptors and other transcription factors (TF) [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] ; and ROCK2, a serine/threonine kinase member of the Rho pathway, involved in cell adhesion, migration, invasion, and mitosis [56] [57] [58] [59] , which may be a potential therapeutic target in human cancer cells and animal models [60] [61] [62] [63] [64] [65] [66] [67] [68] .
Among the genes which do not map at 2p but which are upregulated in 2p gained CLL patients, CAV1 (caveolin-1), mapping to 7q31.1, could be of potential relevance. CAV1 is the major coat protein of caveolae, membrane invaginations involved in multiple cellular functions including molec-ular transport, cell adhesion, and signal transduction [69, 70] . CAV1 has been identified as a tumor suppressor gene in some cancers, whereas in other its up-regulation promotes cell survival, adhesion, and migration [71, 72] . CAV1 expression is elevated in multiple malignancies including breast and prostate cancer, myeloma, thyroid carcinoma, colon, and lung cancer [73] [74] [75] [76] [77] [78] . Furthermore, Joshi et al. [79] defined a feedback loop between Rho/ROCK, Src, and phosphorylated CAV1 in tumor cell protrusions, identifying a novel function for CAV1 in tumor metastasic spreading. More interestingly perhaps, Gilling et al. [80] recently described a critical role for CAV1 in CLL progression involving CLL-tumor microenvironment interaction, specifically immune synapse formation, migration, and proliferation.
Overall, to the best of our knowledge, this is the first comprehensive report providing evidence that 2p gain is an early recurrent chromosomal abnormality in a large prospective series of untreated early-stage CLLs. We identified novel genes found to be modulated in the context of 2p gain which may deserve further investigation to clarify its pathogenetic role in the disease.
